Lyme Treatment Report

www.LymeTreatmentReport.com

admin

Lyme disease bacteria eradicated by new drug in early tests

Lyme disease bacteria eradicated by new drug in early tests

Lyme disease bacteria eradicated by new drug in early tests
AuthorKris Newby
Published on
March 30, 2020
In 2002, my husband and I became seriously ill after a vacation to Martha’s Vineyard. It took ten doctors and a year to discover the root cause: We’d been bitten by unseen ticks harboring the parasites that cause Lyme disease and babesiosis, a malaria-like disease.

Our road to recovery was grueling, requiring five years of

A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome (PLDS)

https://clinicaltrials.gov/ct2/show/NCT04141969

A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome (PLDS)

Detailed Description:
A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome will be evaluated during a double blind, placebo controlled study. This study is an expansion of RLP042019 NCT04078841 Treating Post-Lyme Disease Syndrome With Acetogenins

Study Design
Go to sections
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome
Actual Study Start Date : November 29, 2019
Estimated Primary Completion Date : April 14, 2020
Estimated Study Completion Date : April 28, 2020

BBE31 from the Lyme disease agent Borrelia burgdorferi shows the ability to bind glutathione: potentially opening doors to new strategies to fight against Lyme disease

https://www.sciencedirect.com/science/article/abs/pii/S0304416519302880?via%3Dihub

https://www.ncbi.nlm.nih.gov/pubmed/31785327

BBE31 from the Lyme disease agent Borrelia burgdorferi, known to play an important role in successful colonization of the mammalian host, shows the ability to bind glutathione.

BBE31 from the Lyme disease agent Borrelia burgdorferi shows the ability to bind glutathione: potentially opening doors to new strategies to fight against Lyme disease

Treating Post-Lyme Disease Syndrome With Acetogenins

https://clinicaltrials.gov/ct2/show/NCT04078841

Treating Post-Lyme Disease Syndrome With Acetogenins

Detailed Description:
To access the effectiveness of Acetogenins in treating Post-Lyme Disease Syndrome (PLDS). After failure of antibiotic therapy to relive persistent symptoms of Lyme Disease, the use of Acetogenins to elevate Post-Lyme Disease Syndrome.

Study Design
Go to sections
Study Type : Interventional
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Using ReaLife+ to Treat Post-Lyme Disease Syndrome
Actual Study Start Date : July 1, 2019
Actual Primary Completion Date : November 14, 2019
Estimated Study Completion Date : January 30, 2020

Appropriate laboratory testing in Lyme disease

https://www.mdedge.com/ccjm/article/211289/infectious-diseases/appropriate-laboratory-testing-lyme-disease

https://www.ncbi.nlm.nih.gov/pubmed/31710588

Appropriate laboratory testing in Lyme disease

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

https://clinicaltrials.gov/ct2/show/NCT03891667

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Patients will be randomly assigned to one of two groups:

Treatment Group I- patients will receive Disulfiram for 8 weeks

Treatment Group 2 – patients will receive Disulfiram for 4 weeks followed by 4 weeks of placebo.

The dosing starts at 250 mg on day 1, none on day 2, 250 mg on day 3, none on day 4, and then 250 mg x 3 days. If tolerated, the dose is then increased to 500 mg/day.

Primary outcome is at week 10. Patients will be reassessed at week 14.

Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: This is a placebo-controlled study using matching capsules for disulfiram and placebo. Neither the participant, the care provider, nor the investigator will know the randomized assignment. The research pharmacy and a researcher not involved with this study will keep the code regarding group assignment.
Primary Purpose: Treatment
Official Title: Disulfiram (“Antabuse”): A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
Actual Study Start Date : July 31, 2019
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : March 31, 2021

Combatting Lyme disease myths and the “chronic Lyme industry”

https://www.cmaj.ca/content/191/40/E1111?ijkey=1c206de9ad3ce738490061d59054ba68d2460473&keytype2=tf_ipsecsha

https://www.ncbi.nlm.nih.gov/pubmed/31844026

https://doi.org/10.1503/cmaj.1095806

Combatting Lyme disease myths and the “chronic Lyme industry”
Wendy Glauser
CMAJ October 07, 2019 191 (40) E1111-E1112; DOI: https://doi.org/10.1503/cmaj.1095806

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

https://clinicaltrials.gov/ct2/show/NCT03970733

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 246 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Alternative Schedule Study For VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged 18 To 65 Years – A Randomized, Controlled, Observer-Blind Phase 2 Study
Actual Study Start Date : June 26, 2019
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : March 2021

Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis

https://clinicaltrials.gov/ct2/show/NCT03769194

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study

Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 573 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study.
Actual Study Start Date : December 17, 2018
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : October 2020
Resource links provided by the National Library of Medicine

Different Amoxicillin Treatment Regimens in Erythema Migrans Patients

https://clinicaltrials.gov/ct2/show/NCT03966014

Different Amoxicillin Treatment Regimens in Erythema Migrans Patients

Study Type : Interventional
Estimated Enrollment : 510 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Different Duration and Dosing of Amoxicillin in Patients With Erythema Migrans. A Randomized Clinical Trial.
Actual Study Start Date : June 1, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

UK Lyme disease cases may be three times higher than estimated

https://www.theguardian.com/science/2019/jul/31/uk-lyme-disease-cases-may-be-three-times-higher-than-estimated

UK Lyme disease cases may be three times higher than estimated

Researchers say tick-borne disease ‘is everywhere’ with 8,000 diagnoses likely in 2019

The Challenge of Diagnosing Lyme Disease

https://www.nytimes.com/2019/07/29/well/family/the-challenge-of-diagnosing-lyme-disease.html

The Challenge of Diagnosing Lyme Disease
The biggest problem is that there is no way to test, unequivocally, for the presence of the bacteria that cause the disease.

Research offers possible clues about persistent Lyme disease

https://abcnews.go.com/Health/research-offers-clues-persistent-lyme-disease/story?id=63789776

Research offers possible clues about persistent Lyme disease

New research offers hope on detecting Lyme disease early
Dr. Jennifer Ashton brings all the details on a new study on Lyme disease that is creating a buzz within the medical community.

Inflammatory Mediators in Erythema Migrans

https://clinicaltrials.gov/ct2/show/NCT03956212

Inflammatory Mediators in Erythema Migrans

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 150 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Inflammatory Proteins, Gene Polymorphisms, and Transcriptome Profiles in Patients With Erythema Migrans
Actual Study Start Date : June 1, 2017
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2020

Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel

https://clinicaltrials.gov/ct2/show/NCT03581279

Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: All patients are assigned a unique study ID number to de-identify them.
Primary Purpose: Diagnostic
Official Title: Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel
Actual Study Start Date : May 8, 2018
Estimated Primary Completion Date : October 31, 2019
Estimated Study Completion Date : October 31, 2019

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis [Completed]

https://clinicaltrials.gov/ct2/show/NCT03010228

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 179 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years
Actual Study Start Date : January 2017
Actual Primary Completion Date : September 28, 2017
Actual Study Completion Date : January 16, 2019

An Intervention in a Primary Healthcare Setting to Reduce Lyme Neuroborreliosis Treatment Delay (NBdelay)

https://clinicaltrials.gov/ct2/show/NCT03820999

An Intervention in a Primary Healthcare Setting to Reduce Lyme Neuroborreliosis Treatment Delay (NBdelay)

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Open label interventional study where primary Health care Physicians in areas on Funen Island, Denmark, are included if they have their practice in an area with Lyme Neuroborreliosis incidens > 4.6/100.000
Masking: None (Open Label)
Masking Description: Open label study, due to the intervention (lectures) and the criteria for receiving the intervention (Lyme neuroborreliosis incidens > 4.6/100.000), the study cannot be blinded.
Primary Purpose: Treatment
Official Title: An Intervention in a Primary Healthcare Setting to Reduce Lyme Neuroborreliosis Treatment Delay
Estimated Study Start Date : February 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : April 1, 2021

Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis

https://clinicaltrials.gov/ct2/show/NCT02553473

Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis

Study Type : Interventional
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis; a Multicenter, Non-inferiority, Penta-blind, Randomized Trial
Study Start Date : October 2015
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : October 2020

r/lymedisease – Reddit

https://www.reddit.com/r/lymedisease/

Community for those with lyme disease – Reddit

Back to top